Using AI to predict survival in glioma patients based on histopathology images
Official title: Histopathology Images Based Survival Prediction of Patients With Primary Glioma Using Deep Learning or Machine Learning
Run by The First Affiliated Hospital of Zhengzhou University · NCT04215224 · Data updated 2026-11-12
This study is trying to see if using artificial intelligence to analyze tissue images can help doctors predict how long glioma patients might live.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year to 90 Years |
| Sex | All |
| Enrollment | 3500 (estimated) |
| Sponsor | The First Affiliated Hospital of Zhengzhou University Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Status | Recruiting |
| Started | January 1, 2017 |
| Main results expected | January 1, 2027 |
| Study ends | June 1, 2027 |
| Registry record updated | February 8, 2021 |
| Trial ID | NCT04215224 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a confirmed diagnosis of primary glioma who are undergoing tumor resection and have a life expectancy of more than three months.
✕Probably not a fit
Patients without gliomas, insufficient tumor tissue for molecular analysis, or those with severe systemic malfunctions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry collects clinical, molecular, and histopathology imaging data from glioma patients to develop artificial intelligence algorithms for survival prediction. By analyzing histopathology images and correlating them with detailed survival and molecular pathology data, the study aims to enhance the accuracy of prognosis for glioma patients. The registry will include over 1000 samples, allowing for a robust dataset to refine predictive models and facilitate personalized treatment approaches.
Why it matters
Potential benefit: If successful, this study could provide more accurate survival predictions for glioma patients, leading to better-informed treatment decisions.
How similar studies have gone: Other studies utilizing artificial intelligence for survival prediction in cancer have shown promising results, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfuctions
Where it's running
-
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China Recruiting
Study contacts
- Study coordinator: Zhenyu Zhang, Dr.
- Email: fcczhangzy1@zzu.edu.cn
- Phone: +86 17839973727
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.